Protecting our Pharmaceutical Supply Chain from China Act of 2021

The Protecting our Pharmaceutical Supply Chain from China Act of 2021 aims to reduce U.S. reliance on Chinese-manufactured medications by tracking and eventually restricting their use in federal healthcare programs. The bill would require the FDA to create a registry of drugs and active ingredients sourced from China and mandate that all medication labels clearly list the country of origin for their active ingredients.

For citizens, this legislation would mean that federal programs like Medicare and Medicaid would be prohibited from purchasing drugs with Chinese-made ingredients by 2024, with limited exceptions ending in 2026. Additionally, the bill offers tax incentives to encourage companies to move their pharmaceutical and medical device manufacturing facilities to the United States.